Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antiandrogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in different tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.
Clinical genitourinary cancer. 2022 Nov 11 [Epub ahead of print]
Marta Barrado Los Arcos, Fernando López-Campos, Marta López Valcarcel, Manuel Galdeano Rubio, Ignacio Visus Fernández de Manzanos, Víctor Duque-Santana, Marian Gómez Aparicio, Juan Zafra Martin, Amar U Kishan, Vérane Achard, Shankar Siva, Felipe Couñago
Hospital Universitario de Navarra, Pamplona, Navarra, Spain; Instituto de Investigación Navarra (IdiSNA), Pamplona, Navarra, Spain. Electronic address: ., Hospital Universitario Ramón y Cajal, Madrid, Spain., Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain., Hospital de Terrassa-Consorci Sanitari de Terrassa, Terrasa, Cataluña, Spain., Hospital Universitario de Navarra, Pamplona, Navarra, Spain; Instituto de Investigación Navarra (IdiSNA), Pamplona, Navarra, Spain., Hospital General Universitario de Toledo, Toledo, Spain., Hospital Universitario Virgen de la Victoria, Málaga, Spain; Universidad de Granada, Granada, Spain., University of California, Los Angeles, CA; UCLA Department of Radiation Oncology, Los Angeles, CA., Chief of hôpital fribourgeois (HFR) - freiburger spital (HFR), Fribourg, Switzerland; HUG - Hôpitaux Universitaires de Genève, Geneva, Switzerland., Peter MacCallum Cancer Centre, Melbourne, Australia; University of Melbourne, Melbourne, Australia., San Francisco de Asís Hospital, La Milagrosa Hospital, National Chair of Research and Clinical Trials, Genesis Care, Spain.